Seen Drug Fraud
From Inside a Manufacturer?

For sales, marketing, medical affairs, pricing, and compliance staff. Off-label promotion, kickbacks, and pricing fraud that reach Medicare and Medicaid can violate the False Claims Act, and insiders with firsthand evidence may receive 15–30% of the government's recovery.

Submit Your Information

What is pharmaceutical fraud under the False Claims Act?

It is a drug or device company causing false claims to Medicare, Medicaid or other federal programs, for example through kickbacks to prescribers, off-label promotion, or false price reporting that cuts Medicaid rebates. Claims resulting from an Anti-Kickback Statute violation are false claims by law (42 U.S.C. § 1320a-7b(g)). GlaxoSmithKline paid $3 billion in 2012 to resolve criminal and civil liability over such conduct (DOJ, 2012).

Updated November 2026. General information, not legal advice.

1

Original, Firsthand Information

Your information should come from direct knowledge, such as call notes, sales targets, speaker program records, pricing and rebate calculations, or internal communications. Timing matters: a case generally must be filed within six years of the violation, and never more than ten. (31 U.S.C. § 3731(b))

2

Filed Under Seal in Federal Court

False Claims Act qui tam cases are filed under seal for at least 60 days, meaning the complaint stays confidential while the government investigates and decides whether to intervene. (31 U.S.C. § 3730(b)(2))

3

15–30% of Recovered Funds

If the government intervenes, the whistleblower (called a "relator") generally receives 15–25% of the recovery. If it declines and the relator pursues the case, the share is 25–30%. Courts can award less, for example when a case relies mainly on publicly disclosed information. (31 U.S.C. § 3730(d))

Pharmaceutical and Life Sciences Fraud We Evaluate

Off-Label Promotion

Promoting drugs for uses the FDA has not approved, causing claims to Medicare or Medicaid for uses those programs do not cover. Pfizer's 2009 resolution included $1 billion under the False Claims Act, and six whistleblowers received more than $102 million. (DOJ, 2009)

Kickbacks to Prescribers

Sham speaker programs, honoraria, meals, or consulting fees paid to induce prescriptions. Claims resulting from an Anti-Kickback Statute violation are false claims under the False Claims Act. (42 U.S.C. § 1320a-7b(g))

Speaker Program Schemes

Events with little or no educational content that reward high prescribers. Novartis paid $678 million in 2020 to resolve allegations of this kind first brought to the government by a whistleblower. (DOJ, 2020)

Drug Pricing and Rebate Fraud

Misreporting prices or misclassifying products to underpay Medicaid drug rebates. Mallinckrodt agreed in 2022 to pay about $234.7 million on rebate allegations, and the whistleblower received about $24.7 million. (DOJ, 2022)

Copay and Patient Assistance Schemes

Using a charity or foundation as a conduit to cover patients' copays for a company's own drug. About $26.3 million of the same Mallinckrodt resolution concerned allegations of this kind. (DOJ, 2022)

Manufacturing and Quality Fraud

Selling adulterated drugs made in violation of manufacturing standards to government programs. GSK's 2010 resolution included a $600 million civil settlement, and the whistleblower received about $96 million. (DOJ, 2010)

False Claims Act recoveries exceeded $6.8 billion in fiscal year 2025, the most in the law's history, and more than $5.7 billion involved the health care industry. Prescription drugs were one of three health care areas the Justice Department highlighted. A company found liable generally owes up to three times the government's damages, plus a penalty for each false claim.

Source: U.S. Department of Justice, January 16, 2026; 31 U.S.C. § 3729(a)(1)

Confidential Case Review

For pharmaceutical and life sciences fraud claims with estimated damages exceeding $1M

About your report

Did you learn about this through your work at, or for, the organization involved? *
Is the organization a business, hospital, contractor, or other institution? *

Contact information

How you learned about the conduct

Contractors, vendors, and auditors count as insiders. Tell us what you know directly and what your records show.

Organization and suspected misconduct

Does this involve a company, government agency, or institution? *

We evaluate evidence of systematic fraud involving government payments. Side effects, personal treatment disputes, or individual billing complaints usually fall outside our review.

Claim details and support

Describe the specific scheme, which products it involved, when it happened, and how it reached government programs. 100–1000 characters.

Do records support what you observed? *

Describe the records or observations and what they establish. Do not paste Social Security numbers, patient identifiers, or confidential documents. 20–1000 characters.

Is the conduct still ongoing? *

An estimate helps us understand the matter. If you cannot estimate the amount, choose “Not sure.” Organization size alone does not determine whether we review a submission.

Submit for review

Preparing submission verification...